Brief description not available

Brief description not available

Neuronal injury is the major pathology caused by CNS injuries like stroke or spinal cord injury. However, currently available biomarkers for CNS injuries are either not expressed in neurons at all, or are expressed constitutively in all neurons, regardless of whether the neurons are injured or not. ATF3 as a CNS injury biomarker is revolutionary because its baseline expression in CNS is very low, and it is rapidly induced only in CNS neurons shortly after CNS injuries like stroke or spinal cord injury.  Of note, human serum ATF3 level can be easily measured by a commercially available ELISA kit.

Brief description not available

Researchers at UCSF have developed methods of treating Rheumatoid arthritis and for predicting the response of patients to methotrexate. 

Researchers at UCSF and the Chan Zuckerberg Biohub have identified multiple common autoantibody targets in APS1 patients through proteome-wide programmable phage-display.

Researchers at UCSF and the Chan Zuckerberg Biohub have developed methods to detect SARS-CoV-2 virus.

Researchers at UCSF and the Chan Zuckerberg Biohub have developed a serological detection assay for anti-SARS-CoV-2 antibodies. 

Brief description not available

Brief description not available

In cancer care, specific characteristics of T cells can be used to measure a patient’s response to immunotherapy. Using single-cell RNA-sequencing coupled with TCR sequencing, scientists at UCSF and Harvard detected CD8+ T cell clones shared between blood and tumor in mice and melanoma patients, characterized these matching clones in blood and tumor, and identified potential biomarkers for their isolation in the blood. Their method reveals specific protein signatures (biomarkers) on the surface of T cells that can be therapeutically targeted to treat melanoma and other forms of cancer. It presents a very attractive alternative to obtaining invasive biopsy samples from the tumor, and can be done much more quickly.  

Brief description not available

Brief description not available

Brief description not available

Researchers at UCSF and Chan Zuckerberg Biohub have discovered a novel biomarker for an autoimmune disease that affects patients with testicular cancer.  The disease, known as “testicular cancer-associated paraneoplastic encephalitis,” can cause severe neurological symptoms.  The symptoms include loss of limb control, eye movement, and in some cases, speech.  The disease begins with testicular cancer, which in some cases causes the immune system to attack the brain.  Affected patients are often misdiagnosed and appropriate treatment is delayed. 

A novel monoclonal human antibody specific to the cell-surface exposed protein EphA2, which is over-expressed in many forms of cancer and is a validated therapeutic target.

Biomarkers to predict responsiveness to anti-CTLA-4 antibodies

A novel method to measure airway mucus plugging using CT images from patients with asthma or chronic obstructive pulmonary disease (COPD) patients.

UCSF researchers have developed a novel gut microbiome-based diagnostic test and targeted treatment for early-life identification of atopy or asthma risk in children.

This diagnostic technology uses a panel of 20 biomarkers to diagnose Lyme disease with much higher sensitivity and accuracy than other currently existing methods. Lyme disease can be detected in peripheral blood samples from patients even at early hard-to-diagnose stages. These aspects of the invention make it indispensable for speeding up recovery and prevention of complications associated with this debilitating illness such as carditis, arthritis, neurological illness and even death.

A novel approach for the treatment of lung inflammatory and fibrotic diseases by increased or repaired chitinase function in lung tissues

This invention has provided methods for detecting dyskinesia in Parkinson’s disease patients and provided a way to titrate current treatment to maximize benefits while minimizing side effects.

This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

This invention describes an orientation-independent device that can create bright and highly localized signal enhancement during magnetic resonance imaging.

This mid-pregnancy serum biomarker test can accurately and effectively identify pregnancies that will deliver before 32-weeks of gestation.